Cancer drugs to come under scrutiny

The Drug Utilisation Sub-Committee of the PBAC has flagged several cancer drugs for review at its next meeting. The committee says it will look at predicted versus actual use for: Lenalidomide for myelodysplastic syndrome; Paclitaxel, nanoparticle albumin-bound, for metastatic adenocarcinoma of the pancreas; Eculizumab for atypical haemolytic uraemic syndrome (aHUS); and Sunitinib and everolimus for ...